SCHEMBL2477437

SCHEMBL2477437

CC=Cc1cc([N+](=O)[O-])ccc1-n1cccc(CCO)c1=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
ALDH1A1 P00352 3/20 0.36
POLB P06746 2/20 0.36
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
MAPT P10636 4/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 2/20 0.33
ERN1 O75460 1/20 0.33
CASP1 P29466 1/20 0.33
CASP3 P42574 1/20 0.33
CASP4 P49662 1/20 0.33
CASP7 P55210 1/20 0.33
CASP9 P55211 1/20 0.33
CASP6 P55212 1/20 0.33
MITF O75030 1/20 0.33
ATM Q13315 1/20 0.33
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477436 1.00 TSHR (0.38) TSHRALDH1A1POLBMEN1KMT2A
SCHEMBL3422707 0.84 ERN1 (0.42) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL13272461 0.84 ERN1 (0.42) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL3422710 0.84 ERN1 (0.42) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL2473827 0.83 F2 (0.41) TSHRALDH1A1POLBMEN1KMT2A
SCHEMBL3060321 0.82 CHEK1 (0.38) TSHRALDH1A1POLBMEN1KMT2A
SCHEMBL2477838 0.82 CHEK1 (0.38) TSHRALDH1A1POLBMEN1KMT2A
SCHEMBL2474273 0.81 NR1H2 (0.36) TSHRALDH1A1POLBMEN1KMT2A
SCHEMBL2474270 0.81 NR1H2 (0.36) TSHRALDH1A1POLBMEN1KMT2A
SCHEMBL3419897 0.80 MAPT (0.43) ALDH1A1MEN1KMT2AMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487111-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-16 US disclosed
US-8487111-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-16 US disclosed
EP-2173744-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION Bayer Pharma AG (DE) 2011-10-05 EP disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L TSHR 4139/4885ALDH1A1 523/4885POLB 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.